Nature Reviews Cancer

Article	Citations
Computing brain metastasis impact	705
Digging for treasures in the tumour interactome	679
Combining spatial transcriptomics and AI to enhance brain tumour diagnosis	483
Combinatorial strategies to target RAS-driven cancers	475
Claudin proteins as emerging therapeutic targets for solid tumours	462
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	418
Emerging strategies to investigate the biology of early cancer	375
Exploiting metabolic cell death for cancer therapy	368
Oncofetal reprogramming in tumour development and progression	302
INVADEseq to study the intratumoural microbiota at host single-cell resolution	295
Fructose takes a detour to feed cancer	292
Implementing practice-changing progress for managing cancer of unknown primary	290
Mapping the prostate cell family tree	276
Fighting cancer with fat	271
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’	262
The evolution of cancer and ageing: a history of constraint	260
Tertiary lymphoid structures as hubs of antitumour immunity	255
3D chromatin architecture as a predictor of somatic mutations in cancer genomes	252
Connie J. Eaves (1944–2024)	250
The recruitment of metastasis-associated monocytes	248
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	223
How medical anthropology can contribute to cancer research	220
Translating premalignant biology to accelerate non-small-cell lung cancer interception	214
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	212
Avoiding cancer through collective behaviour	209

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies	199
Epithelial and stromal co-evolution and complicity in pancreatic cancer	194
Nanoreceptors take down mutant p53	192
Impersonating neurons	188
Tumour EVPs disrupt liver function	187
AACR 2025	185
Measuring HLA disruption using MHC Hammer	183
Gut microbes produce novel genotoxic metabolites	182
Persistence is key	174
Thelpers? More like Ttroublemakers	171
Defining a ‘cells to society’ research framework for appendiceal tumours	166
No mutation, tumour initiation	164
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer	164
3D bioprinted cancer models: from basic biology to drug development	160
Rethinking ovarian cancer III: the past decade and future directions	157
Dendritic cells rise and shine	153
Removing barriers to address sex differences in anticancer drug toxicity	151
Natural killer cells in antitumour adoptive cell immunotherapy	148
How chemokines organize the tumour microenvironment	148
B-ring sterols to the rescue	139
Bone voyage: immune crosstalk sets sail	139
Visualizing intratumoural heterogeneity with EpicMIBI	128
Double trouble for the tumour glycocode	127
Identifying spatial cellular structures with SPACE-GM	126
In-depth organoid profiling of pancreatic cancer	123
Environmental endocrine disruptors: rethinking the origins of early-onset ER+ breast cancer	120
Enhancer and metabolic rewiring by KMT2C–COMPASS or KMT2D–COMPASS family loss in cancer creates druggable vulnerabilities	118
Context-dependent synthetic lethality — an emerging precision therapeutic approach	115
Opportunities and challenges of targeting cGAS–STING in cancer	113
Linking cell mechanical memory and cancer metastasis	109
The path to leptomeningeal metastasis	108
The immune microenvironment of colorectal cancer	104
Dynamics and specificities of T cells in cancer immunotherapy	101
Metabolic interplays between the tumour and the host shape the tumour macroenvironment	98
Regulatory T cells in the tumour microenvironment	98
Leveraging the replication stress response to optimize cancer therapy	95
Encoding spatial tumour dynamics with Starfysh	94
Understanding and addressing race disparities in childhood cancer outcomes	94
Race influences the tumour microbiome	94
Cancer nanomedicine	91
Deciphering the cancer genome and epigenome	91
Advancing AI for multi-omics and clinical data integration in basic and translational cancer research	83
The link between vitamin D and prostate cancer	81
RNA splicing dysregulation and the hallmarks of cancer	76
ER stress sparks nerve pain	73
Being in the zone	69
Re-routing IgE for cancer therapy	68
Polygenic scores in cancer	68
Targeted protein degradation for cancer therapy	66
Acetyl-CoA metabolism in cancer	66

Z-nucleic acids give immunotherapy a boost	65
Local CAR manufacturing	64
Tamoxifen takes the wheel	62
Right ON target: a new RAS-GTP inhibitor	61
Integrative medicine in oncology: redefining the standard of care	61
Prime editing GEMMs to model cancer mutations	61
When the time is right	60
Chromothripsis in cancer	59
Decoding cancer across scales with metabolomics	59
Expanding the utility of precision oncology knowledge bases	59
NOTUM-mediated stem cell competition in CRC	59
Tertiary lymphoid structures in anticancer immunity	59
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities	59
In vivo labelling system to study cell neighbourhoods	52
Defining precancer: a grand challenge for the cancer community	52
Revealing genomic secrets of archival FFPE samples	51
New pathogen on the block	50
Judith Campisi (1948–2024)	50
N6-Methyladenosine: an RNA modification as a central regulator of cancer	49
Inferring cancer metabolism from gene-expression data	49
Melanomagenesis antagonizes stem cell ageing	49
Cancer risk in children with congenital anomalies	48
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	46
The present and future of the Cancer Dependency Map	46
Recent advances in therapeutic cancer vaccines	45
Carcinogenesis at single-cell resolution	44
Patient-derived organoids unveil sarcoma vulnerabilities	39
Global post-mortem tissue donation programmes to accelerate cancer research	38
Transfer RNAs as dynamic and critical regulators of cancer progression	38
Focusing on the complex and dynamic interplay between ageing and cancer	38
Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy	37
Traject3d for studying 3D cellular heterogeneity	36
A timeline of tumour-associated macrophage biology	36
Epigenomic heterogeneity as a source of tumour evolution	36
Developing dietary interventions as therapy for cancer	36
Digitally enhanced Raman spectroscopy	35
Author Correction: Integrative medicine in oncology: redefining the standard of care	33
Harnessing the influenza virus to fight cancer	33
We cannot ignore the cancer risks of wildfires	31
Mechanisms, challenges and opportunities for FLASH radiotherapy in cancer	31
Guardrails for the use of generalist AI in cancer care	30
Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity	30
Targeting cancer cell dormancy	29
Fcγ receptors and immunomodulatory antibodies in cancer	27
Neuro-immune cross-talk in cancer	27
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity	26
Structural variations in cancer and the 3D genome	26
AACR 2024	23
mRNA-based cancer therapeutics	23
The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment	22
Next-generation epidemiologic cohorts for cancer aetiology	22
Fungi in cancer: not such a ‘fun-guy’	22
Male melanoma comes of age	22
EMT in chemoresistance	21
Decoding the functional impact of the cancer genome through protein–protein interactions	20
Modelling and deciphering tumour metabolism in CRISPR screens	20
Mechanisms driving the immunoregulatory function of cancer cells	20
Advances in cutaneous squamous cell carcinoma	19
Key role for microbiota in gut–bone crosstalk	19
CAFs promote CRPC	19
Energizing leukaemia	18
Same same but different	18
Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situ	15
Deep tissue imaging of cancer in the infrared	14
l-Fucose: a dietary sugar with multifaceted potential in the biology and therapy of cancer	14
Advances in translational research of the rare cancer type adrenocortical carcinoma	14
Decoding the basis of histological variation in human cancer	14
Inherited resilience	13
Artificial intelligence-generated synthetic data for cancer research and clinical trials	13
Multiomics-guided cellular immunotherapies	12
Inflammatory neutrophils	11
Air pollution promotes tumorigenesis through pre-existing oncogenic mutations	10
Stemness in solid malignancies: coping with immune attack	10
Enhanced transposable elements	10
Therapeutic resistance to anti-oestrogen therapy in breast cancer	10
Mapping out mitochondria	10
Glioblastomas remodel neural circuits	10
Black voices in cancer research and oncology	9
Androgen receptor activation for breast cancer therapy	9
Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection	9

Too much of a good thing	9
Overcoming heterogeneity with 3D whole-tumour sampling	9
Big data in basic and translational cancer research	9
Targeting sex steroid biosynthesis for breast and prostate cancer therapy	8
Addressing the gaps in cancer screening for LGBTQ+ individuals	8
A fatty competitor in tumour immunity	8
Pathogenesis of cancers derived from thyroid follicular cells	8
Limiting bias in AI models for improved and equitable cancer care	7
Breast milk for breast cancer detection	7
Fungi in cancer	7
Intercepting gastric cancer	7
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment	7
Aristolochic acid-associated cancers: a public health risk in need of global action	7
Feeding latent brain metastasis	7
Nucleotide metabolism: a pan-cancer metabolic dependency	7
The fibroinflammatory response in cancer	6
Understanding tumour endothelial cell heterogeneity and function from single-cell omics	6
Tumour avatars to model patients’ responses to immunotherapy	6
Microbiota and immune-related adverse events in cancer immunotherapy	6
Modelling the ageing dependence of cancer evolutionary trajectories	6
Conventional chemotherapy: millions of cures, unresolved therapeutic index	6
Proximity labelling to study chromatin interactomes	6
Functional m6A site detection by FOCAS	6
Defining and using immune archetypes to classify and treat cancer	5
Protection against tumour formation	5
Obesity as a promoter in BRCA mutation carriers	5
VIBRANT: mapping cell phenotypes using vibrational spectroscopy	5
Epigenetic memory	5
Small speckles, big impact	5
Replication timings affect the frequency of chromosomal translocation	4
Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	4
scAtlasVAE: a deep learning framework for generating a human CD8+ T cell atlas	4
The dynamic role of platelets in cancer progression and their therapeutic implications	4
A machine learning toolkit for subtyping cancer in existing and new datasets	4
Targeting the roots of myeloid malignancies with T cell receptors	4
Tracing the evolutionary history of breast cancer	4
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications	3
Hidden epithelial subtypes refine colorectal cancer classification	3
Taking a detour	3
Targeting the tumour’s little helpers	3
Targeting aberrant splicing	3
Advancing cancer research via comparative oncology	3
Rusting away with age	3
Lactate gives a sour taste	3
Heard immunity in CAR T cells	3
Multiplex protein imaging in tumour biology	3
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance	3
Aggregating premalignancy	3
Mastering the use of cellular barcoding to explore cancer heterogeneity	3
Oncologists must act to manage cancer detected through prenatal screening	3
Cancer’s sensory experience	3
Author Correction: The importance of 3D fibre architecture in cancer and implications for biomaterial model design	3
Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities	3
Sex affects cancer genomes	3
Exploiting temporal aspects of cancer immunotherapy	3
Lymphatic vessels in the age of cancer immunotherapy	3
Stromal cells drive tumorigenesis in BRCA1 mutation carriers	3
NET-working under stress	3
Identification, functional insights and therapeutic targeting of EMT tumour states	3
Epigenetic lesions drive gliomagenesis	3
How protons pave the way to aggressive cancers	3
PDX models for functional precision oncology and discovery science	3
Ageing lipids map melanoma’s journey	3
Managing cancer following the World Trade Center disaster	2
Allies in the epidermis	2
Activated neutrophils: the anti-hero	2
Stromal senescence contributes to age-related increases in cancer	2
Unlocking the potential of FinnGen to advance cancer research	2
Challenging the status quo to improve the translational potential of preclinical oncology studies	2
Cancers make their own luck: theories of cancer origins	2
The advent of immune stimulating CAFs in cancer	2
Translating p53-based therapies for cancer into the clinic	2
How cancer reduces motivation	2
Tumour hypoxia in driving genomic instability and tumour evolution	2
Liquid biopsies for Hodgkin lymphoma	2
A guide to transcriptomic deconvolution in cancer	2
Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment	2
Revisiting the TGFβ paradox: insights from HPV-driven cancer and the DNA damage response	2
Characterization of the B cell receptor repertoire in melanoma	2
Towards targeting transposable elements for cancer therapy	2
Why do patients with cancer die?	2
STAT proteins in cancer: orchestration of metabolism	2
Tryptophan metabolite improves PDAC response rates and survival	2
Preprints as tools to advance careers	2
Salmonella, the insidious contributor to gallbladder and colon cancers	2
Pressing defence	2
Striking the right balance with type I interferon signalling in cancer	2
Eph receptors and ephrins in cancer progression	2
Unlocking the potential of urine-based liquid biopsy through improved reporting and standardization	2
Investigating immune cells across time in vivo	2
Cancer burden in low-income and middle-income countries	2
Circular RNA in cancer	2
Cancer progression through the lens of age-induced metabolic reprogramming	2
The rise of spatial insights into tumour tissue architecture	2
Unravelling the genetics and epigenetics of the ageing tumour microenvironment in cancer	2